Friday, September 14, 2012

MethylGene announces encouraging data from candidiasis study



MethylGene Inc., a clinical-stage biopharmaceutical company, has announced the preclinical data for the company's novel clinical-stage antifungal, MGCD290.
The study, MGCD290, an oral fungal Hos2 inhibitor, enhances the antifungal properties of fluconazole following multiple or single oral dose administration in pre- and post-infection settings, demonstrated that MGCD290 plus fluconazole was superior to fluconazole alone in a murine model of systemic candidiasis under multiple dosing schedules.
Fluconazole is the most widely used triazole antifungal, and previous in vitro and in vivo studies have established that MGCD290 enhances the antifungal activity of fluconazole, broadening its spectrum of activity and increasing the sensitivity of fungi to fluconazole.